FDAsafety guidance72% confidence
FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (nmus rehab) as pain management therapies.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Musculoskeletal · Chronic Pain
- Sub-indication
- Nmus Rehab
Related signal: Study on Music Therapy's Effects in Chronic Neck Pain Rehabilitation